NASDAQ: RAPP
Rapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?

Insider buying vs selling

Have Rapport Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Abraham CeesayCEO2026-09-081,069$46.02
$49.19kSell
Abraham CeesayCEO2026-09-087,141$45.56
$325.31kSell
Krishnaswamy YeleswaramCXO2026-08-2516,201$51.06
$827.19kSell
Krishnaswamy YeleswaramCXO2026-08-2520,799$50.31
$1.05MSell
Abraham CeesayCEO2026-08-2518,921$49.57
$937.95kSell
Krishnaswamy YeleswaramCXO2026-08-2413,160$50.00
$657.97kSell
Krishnaswamy YeleswaramCXO2026-08-19404$49.90
$20.16kSell
Abraham CeesayCEO2026-08-1119,500$48.04
$936.84kSell
Abraham CeesayCEO2026-08-115,794$48.62
$281.72kSell
Abraham CeesayCEO2026-08-113,664$46.90
$171.84kSell

1 of 8

RAPP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RAPP insiders and whales buy or sell their stock.

RAPP Shareholders

What type of owners hold Rapport Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Third Rock Ventures V LP15.11%7,249,743$300.07MInsider
Arch Venture Partners XII LLC7.77%3,728,738$154.33MInsider
James Healy4.16%1,995,594$82.60MInsider
Abraham Ceesay1.38%663,893$27.48MInsider
Steven M. Paul1.08%519,308$21.49MInsider
David Bredt0.82%393,075$16.27MInsider
Bradley S. Galer0.41%197,426$8.17MInsider
Krishnaswamy Yeleswaram0.41%195,862$8.11MInsider
Cheryl Gault0.31%149,914$6.20MInsider
Reid M. Huber0.04%20,400$844.36kInsider

1 of 3

RAPP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RAPP0.11%31.54%Net SellingNet Selling
AGIO0.11%32.66%Net SellingNet Selling
ADMA0.09%25.11%Net SellingNet Selling
VCEL0.11%10.19%Net SellingNet Selling
GHRS0.08%21.86%

Rapport Therapeutics Stock Ownership FAQ

Who owns Rapport Therapeutics?

Rapport Therapeutics (NASDAQ: RAPP) is owned by 0.11% institutional shareholders, 31.54% Rapport Therapeutics insiders, and 68.35% retail investors. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 7.25M shares representing 15.11% of the company. Third Rock Ventures V LP's Rapport Therapeutics shares are currently valued at $304.13M.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.